Logo image of BHVN

BIOHAVEN LTD (BHVN) Stock Fundamental Analysis

NYSE:BHVN - New York Stock Exchange, Inc. - VGG1110E1079 - Common Stock - Currency: USD

14.39  -0.17 (-1.17%)

After market: 14.4301 +0.04 (+0.28%)

Fundamental Rating

2

Taking everything into account, BHVN scores 2 out of 10 in our fundamental rating. BHVN was compared to 557 industry peers in the Biotechnology industry. While BHVN seems to be doing ok healthwise, there are quite some concerns on its profitability. BHVN does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year BHVN has reported negative net income.
BHVN had a negative operating cash flow in the past year.
In the past 5 years BHVN always reported negative net income.
In the past 5 years BHVN always reported negative operating cash flow.
BHVN Yearly Net Income VS EBIT VS OCF VS FCFBHVN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -200M -400M -600M -800M

1.2 Ratios

With a Return On Assets value of -193.62%, BHVN is not doing good in the industry: 88.87% of the companies in the same industry are doing better.
With a Return On Equity value of -342.43%, BHVN is not doing good in the industry: 74.69% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -193.62%
ROE -342.43%
ROIC N/A
ROA(3y)-101.1%
ROA(5y)-112.04%
ROE(3y)-133.7%
ROE(5y)-344.72%
ROIC(3y)N/A
ROIC(5y)N/A
BHVN Yearly ROA, ROE, ROICBHVN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2K 4K 6K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for BHVN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BHVN Yearly Profit, Operating, Gross MarginsBHVN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

5

2. Health

2.1 Basic Checks

The number of shares outstanding for BHVN has been increased compared to 1 year ago.
The number of shares outstanding for BHVN has been increased compared to 5 years ago.
There is no outstanding debt for BHVN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
BHVN Yearly Shares OutstandingBHVN Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
BHVN Yearly Total Debt VS Total AssetsBHVN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

BHVN has an Altman-Z score of -6.43. This is a bad value and indicates that BHVN is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -6.43, BHVN is doing worse than 65.89% of the companies in the same industry.
There is no outstanding debt for BHVN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -6.43
ROIC/WACCN/A
WACCN/A
BHVN Yearly LT Debt VS Equity VS FCFBHVN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M -400M

2.3 Liquidity

A Current Ratio of 2.33 indicates that BHVN has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 2.33, BHVN is doing worse than 71.63% of the companies in the same industry.
BHVN has a Quick Ratio of 2.33. This indicates that BHVN is financially healthy and has no problem in meeting its short term obligations.
BHVN has a worse Quick ratio (2.33) than 69.66% of its industry peers.
Industry RankSector Rank
Current Ratio 2.33
Quick Ratio 2.33
BHVN Yearly Current Assets VS Current LiabilitesBHVN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

3

3. Growth

3.1 Past

BHVN shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -37.04%.
EPS 1Y (TTM)-37.04%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%1.36%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

BHVN is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 13.48% yearly.
The Revenue is expected to grow by 183.30% on average over the next years. This is a very strong growth
EPS Next Y23.07%
EPS Next 2Y16.34%
EPS Next 3Y14.92%
EPS Next 5Y13.48%
Revenue Next Year132.82%
Revenue Next 2Y273.96%
Revenue Next 3Y272.98%
Revenue Next 5Y183.3%

3.3 Evolution

BHVN Yearly Revenue VS EstimatesBHVN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2024 2025 2026 2027 2028 2029 2030 2031 2032 1B 2B 3B
BHVN Yearly EPS VS EstimatesBHVN Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 5 -5 -10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for BHVN. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for BHVN. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BHVN Price Earnings VS Forward Price EarningsBHVN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BHVN Per share dataBHVN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 -4 -6 -8

4.3 Compensation for Growth

BHVN's earnings are expected to grow with 14.92% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y16.34%
EPS Next 3Y14.92%

More info and screens

0

5. Dividend

5.1 Amount

BHVN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BIOHAVEN LTD

NYSE:BHVN (6/18/2025, 8:04:00 PM)

After market: 14.4301 +0.04 (+0.28%)

14.39

-0.17 (-1.17%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-12 2025-05-12/amc
Earnings (Next)08-05 2025-08-05/bmo
Inst Owners87.79%
Inst Owner Change8.32%
Ins Owners11.53%
Ins Owner Change0.15%
Market Cap1.47B
Analysts86.36
Price Target55.55 (286.03%)
Short Float %12.45%
Short Ratio4.81
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-20.46%
Min EPS beat(2)-25.54%
Max EPS beat(2)-15.38%
EPS beat(4)1
Avg EPS beat(4)-35.24%
Min EPS beat(4)-101.89%
Max EPS beat(4)1.84%
EPS beat(8)1
Avg EPS beat(8)-27.54%
EPS beat(12)3
Avg EPS beat(12)-37.32%
EPS beat(16)3
Avg EPS beat(16)-33.19%
Revenue beat(2)0
Avg Revenue beat(2)-100%
Min Revenue beat(2)-100%
Max Revenue beat(2)-100%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-6.47%
PT rev (3m)-15.91%
EPS NQ rev (1m)1.94%
EPS NQ rev (3m)-0.98%
EPS NY rev (1m)0%
EPS NY rev (3m)-10.47%
Revenue NQ rev (1m)-100%
Revenue NQ rev (3m)-100%
Revenue NY rev (1m)-31.53%
Revenue NY rev (3m)-29.74%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 5.66
P/tB 6.13
EV/EBITDA N/A
EPS(TTM)-9.36
EYN/A
EPS(NY)-6.07
Fwd EYN/A
FCF(TTM)-6.36
FCFYN/A
OCF(TTM)-6.32
OCFYN/A
SpS0
BVpS2.54
TBVpS2.35
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -193.62%
ROE -342.43%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-101.1%
ROA(5y)-112.04%
ROE(3y)-133.7%
ROE(5y)-344.72%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 47.02%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.33
Quick Ratio 2.33
Altman-Z -6.43
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)177.45%
Cap/Depr(5y)891.42%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-37.04%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%1.36%
EPS Next Y23.07%
EPS Next 2Y16.34%
EPS Next 3Y14.92%
EPS Next 5Y13.48%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year132.82%
Revenue Next 2Y273.96%
Revenue Next 3Y272.98%
Revenue Next 5Y183.3%
EBIT growth 1Y-70.53%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year17.65%
EBIT Next 3Y7.7%
EBIT Next 5Y14.4%
FCF growth 1Y-100.9%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-103.78%
OCF growth 3YN/A
OCF growth 5YN/A